What is Sun Biopharma?
Sun Biopharma is a clinical-stage biopharmaceutical enterprise dedicated to the development of disruptive therapeutics for patients facing urgent, unmet medical needs. The company's primary focus is the advancement of SBP-101, a novel candidate currently being evaluated for the treatment of metastatic pancreatic ductal adenocarcinoma. By leveraging scientific collaborations with global research institutions and maintaining a robust Data Safety Monitoring Board, Sun Biopharma positions itself at the intersection of academic innovation and commercial drug development. The firm's operational model emphasizes high-impact clinical trials and strategic partnerships to validate the efficacy of its pipeline in complex cancer environments.
How much funding has Sun Biopharma raised?
Sun Biopharma has raised a total of $6.9M across 3 funding rounds:
Debt
$2.3M
Debt
$3.1M
Debt
$1.5M
Debt (2013): $2.3M, investors not publicly disclosed
Debt (2014): $3.1M, investors not publicly disclosed
Debt (2017): $1.5M, investors not publicly disclosed
Key Investors in Sun Biopharma
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Sun Biopharma?
With the recent capital injection, Sun Biopharma is well-positioned to accelerate its clinical trial programs and expand the therapeutic scope of SBP-101. The company's strategic roadmap involves deepening its collaborative research efforts with international cancer centers to explore combination therapies and broader oncology applications. As the firm transitions through its current lifecycle stage, the focus will remain on achieving key clinical milestones that demonstrate safety and efficacy, ultimately aiming to provide transformative solutions for patients with pancreatic cancer. Continued investment will likely support the scaling of these research initiatives and the strengthening of the company's intellectual property portfolio.
See full Sun Biopharma company page
